{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:02:33Z","timestamp":1794110553309,"version":"4.8.0"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.pharmthera.2021.107989","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T10:33:04Z","timestamp":1630751584000},"page":"107989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":182,"special_numbering":"C","title":["CX3CL1\/CX3CR1 signaling targets for the treatment of neurodegenerative diseases"],"prefix":"10.1016","volume":"231","author":[{"given":"Meena S.","family":"Subbarayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Joly-Amado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula C.","family":"Bickford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pharmthera.2021.107989_bb0005","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.4049\/jimmunol.172.10.6362","article-title":"The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10","volume":"172","author":"Abel","year":"2004","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0010","series-title":"Huntington disease","author":"Ajitkumar","year":"2021"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","article-title":"Biology of Parkinson\u2019s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder","volume":"6","author":"Alexander","year":"2004","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nbd.2014.11.009","article-title":"Role of fractalkine\u2013CX3CR1 pathway in seizure-induced microglial activation, neurodegeneration, and neuroblast production in the adult rat brain","volume":"74","author":"Ali","year":"2015","journal-title":"Neurobiology of Disease"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/00001199-199309000-00007","article-title":"Postconcussive symptoms after uncomplicated mild head injury","volume":"8","author":"Alves","year":"1993","journal-title":"The Journal of Head Trauma Rehabilitation"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107989_bb0030","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40263-017-0483-3","article-title":"Targeting neuroinflammation to treat Alzheimer\u2019s disease","volume":"31","author":"Ardura-Fabregat","year":"2017","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/00207454.2012.723079","article-title":"Fractalkine gene receptor polymorphism in patients with multiple sclerosis","volume":"123","author":"Arli","year":"2013","journal-title":"The International Journal of Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/00207454.2012.723079","article-title":"Fractalkine gene receptor polymorphism in patients with multiple sclerosis","volume":"123","author":"Arli","year":"2012","journal-title":"International Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.npep.2019.04.001","article-title":"Effect of mesenchymal stem cells on glial cells population in cuprizone induced demyelination model","volume":"75","author":"Barati","year":"2019","journal-title":"Neuropeptides"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ncpneuro0113","article-title":"Mechanisms of disease: Neuropathic pain\u2014A clinical perspective","volume":"2","author":"Baron","year":"2006","journal-title":"Nature Clinical Practice. Neurology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0055","doi-asserted-by":"crossref","first-page":"689332","DOI":"10.3389\/fncel.2021.689332","article-title":"Huntingtin and the synapse","volume":"15","author":"Barron","year":"2021","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0060","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12974-018-1310-6","article-title":"Genetically enhancing the expression of chemokine domain of CX(3)CL1 fails to prevent tau pathology in mouse models of tauopathy","volume":"15","author":"Bemiller","year":"2018","journal-title":"Journal of Neuroinflammation"},{"issue":"19","key":"10.1016\/j.pharmthera.2021.107989_bb0065","doi-asserted-by":"crossref","first-page":"10432","DOI":"10.1073\/pnas.94.19.10432","article-title":"Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures","volume":"94","author":"Bengzon","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nbd.2009.11.009","article-title":"Promoting axonal rewiring to improve outcome after stroke","volume":"37","author":"Benowitz","year":"2010","journal-title":"Neurobiology of Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuron.2010.08.023","article-title":"Regulation of tau pathology by the microglial fractalkine receptor","volume":"68","author":"Bhaskar","year":"2010","journal-title":"Neuron"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2021.107989_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2008.04.012","article-title":"Neuron-microglia signaling: Chemokines as versatile messengers","volume":"198","author":"Biber","year":"2008","journal-title":"Journal of Neuroimmunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107989_bb0085","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1089\/neu.2018.6096","article-title":"Experimental designs for repeated mild traumatic brain injury: Challenges and considerations","volume":"36","author":"Bolton-Hall","year":"2019","journal-title":"Journal of Neurotrauma"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0090","article-title":"Increased expression of the chemokine fractalkine in Crohn\u2019s disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype","volume":"101","author":"Brand","year":"2006","journal-title":"Official Journal of the American College of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0095","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fnins.2016.00526","article-title":"Loss of fractalkine signaling exacerbates axon transport dysfunction in a chronic model of glaucoma","volume":"10","author":"Breen","year":"2016","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fncel.2014.00117","article-title":"Microglia centered pathogenesis in ALS: Insights in cell interconnectivity","volume":"8","author":"Brites","year":"2014","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2011.11.006","article-title":"CX(3)CR1 drives cytotoxic CD4(+)CD28(\u2212) T cells into the brain of multiple sclerosis patients","volume":"38","author":"Broux","year":"2012","journal-title":"Journal of Autoimmunity"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0896-6273(00)80272-X","article-title":"ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions","volume":"18","author":"Bruijn","year":"1997","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.25653","article-title":"Common polymorphisms of chemokine (C-X3-C motif) receptor 1 gene modify amyotrophic lateral sclerosis outcome: A population-based study","volume":"57","author":"Calvo","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0120","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nn1715","article-title":"Control of microglial neurotoxicity by the fractalkine receptor","volume":"9","author":"Cardona","year":"2006","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fncel.2018.00365","article-title":"Role of the fractalkine receptor in CNS autoimmune inflammation: New approach utilizing a mouse model expressing the human CX3CR1(I249\/M280) variant","volume":"12","author":"Cardona","year":"2018","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107989_bb0130","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/glia.23338","article-title":"Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease","volume":"66","author":"Castro-S\u00e1nchez","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.csbj.2016.02.001","article-title":"Network analysis of human post-mortem microarrays reveals novel genes, microRNAs, and mechanistic scenarios of potential importance in fighting huntington\u2019s disease","volume":"14","author":"Chandrasekaran","year":"2016","journal-title":"Computational and Structural Biotechnology Journal"},{"issue":"15","key":"10.1016\/j.pharmthera.2021.107989_bb0140","doi-asserted-by":"crossref","first-page":"RC87","DOI":"10.1523\/JNEUROSCI.20-15-j0004.2000","article-title":"Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage","volume":"20","author":"Chapman","year":"2000","journal-title":"The Journal of Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0145","first-page":"1373","article-title":"A novel CX3CR1 inhibitor AZD8797 facilitates early recovery of rat acute spinal cord injury by inhibiting inflammation and apoptosis","volume":"45","author":"Chen","year":"2020","journal-title":"International Journal of Molecular Medicine"},{"issue":"37","key":"10.1016\/j.pharmthera.2021.107989_bb0150","doi-asserted-by":"crossref","first-page":"32713","DOI":"10.1074\/jbc.M111.254268","article-title":"CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease","volume":"286","author":"Cho","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"issue":"45","key":"10.1016\/j.pharmthera.2021.107989_bb0155","doi-asserted-by":"crossref","first-page":"16327","DOI":"10.1523\/JNEUROSCI.3611-11.2011","article-title":"CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents","volume":"31","author":"Cipriani","year":"2011","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"issue":"21","key":"10.1016\/j.pharmthera.2021.107989_bb0160","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1523\/JNEUROSCI.0828-09.2009","article-title":"The liberation of fractalkine in the dorsal horn requires microglial cathepsin S","volume":"29","author":"Clark","year":"2009","journal-title":"The Journal of Neuroscience"},{"issue":"25","key":"10.1016\/j.pharmthera.2021.107989_bb0165","doi-asserted-by":"crossref","first-page":"10655","DOI":"10.1073\/pnas.0610811104","article-title":"Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain","volume":"104","author":"Clark","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0170","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.expneurol.2011.09.012","article-title":"Microglial signalling mechanisms: Cathepsin S and Fractalkine","volume":"234","author":"Clark","year":"2012","journal-title":"Experimental Neurology"},{"issue":"121","key":"10.1016\/j.pharmthera.2021.107989_bb0175","article-title":"Fractalkine\/CX3CR1 signaling during neuropathic pain","volume":"8","author":"Clark","year":"2014","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107989_bb0180","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1128\/MCB.21.9.3159-3165.2001","article-title":"Generation and analysis of mice lacking the chemokine fractalkine","volume":"21","author":"Cook","year":"2001","journal-title":"Molecular and Cellular Biology"},{"issue":"19","key":"10.1016\/j.pharmthera.2021.107989_bb0185","doi-asserted-by":"crossref","first-page":"19649","DOI":"10.1074\/jbc.M313457200","article-title":"Enhanced adhesive capacities of the naturally occurring Ile249\u2013Met280 variant of the chemokine receptor CX3CR1*","volume":"279","author":"Daoudi","year":"2004","journal-title":"Journal of Biological Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0190","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1046\/j.1460-9568.2000.00140.x","article-title":"Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus","volume":"12","author":"De Simoni","year":"2000","journal-title":"The European Journal of Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107989_bb0195","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/j.1460-9568.2004.03800.x","article-title":"Fractalkine reduces N-methyl-d-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation","volume":"20","author":"Deiva","year":"2004","journal-title":"The European Journal of Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107989_bb0200","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/jcbfm.2008.64","article-title":"Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse","volume":"28","author":"D\u00e9nes","year":"2008","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"27","key":"10.1016\/j.pharmthera.2021.107989_bb0205","doi-asserted-by":"crossref","first-page":"9910","DOI":"10.1523\/JNEUROSCI.2114-11.2011","article-title":"Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo\/iNOS+ macrophages","volume":"31","author":"Donnelly","year":"2011","journal-title":"The Journal of Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0210","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/nbdi.2000.0292","article-title":"Differential screening of mutated SOD1 transgenic mice reveals early up-regulation of a fast axonal transport component in spinal cord motor neurons","volume":"7","author":"Dupuis","year":"2000","journal-title":"Neurobiology of Disease"},{"issue":"10107","key":"10.1016\/j.pharmthera.2021.107989_bb0215","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"van Es","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107989_bb0220","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1084\/jem.20182238","article-title":"The intracellular domain of CX3CL1 regulates adult neurogenesis and Alzheimer\u2019s amyloid pathology","volume":"216","author":"Fan","year":"2019","journal-title":"The Journal of Experimental Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0225","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1523\/JNEUROSCI.1333-19.2019","article-title":"Activated CX3CL1\/Smad2 signals prevent neuronal loss and Alzheimer\u2019s tau pathology-mediated cognitive dysfunction","volume":"40","author":"Fan","year":"2020","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0230","first-page":"792","article-title":"An early and late peak in microglial activation in Alzheimer's disease trajectory","volume":"140","author":"Fan","year":"2017","journal-title":"Brain"},{"issue":"5461","key":"10.1016\/j.pharmthera.2021.107989_bb0235","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1126\/science.287.5461.2274","article-title":"Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1","volume":"287","author":"Faure","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0240","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12974-015-0386-5","article-title":"Time-dependent effects of CX3CR1 in a mouse model of mild traumatic brain injury","volume":"12","author":"Febinger","year":"2015","journal-title":"Journal of Neuroinflammation"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0245","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11481-018-9822-5","article-title":"CNS-wide over expression of fractalkine improves cognitive functioning in a tauopathy model","volume":"14","author":"Finneran","year":"2019","journal-title":"J Neuroimmune Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0250","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0255","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12974-017-0840-7","article-title":"Proteomic analysis of aged microglia: Shifts in transcription, bioenergetics, and nutrient response","volume":"14","author":"Flowers","year":"2017","journal-title":"Journal of Neuroinflammation"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107989_bb0260","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1515\/hsz-2013-0189","article-title":"Cathepsin S generates soluble CX3CL1 (fractalkine) in vascular smooth muscle cells","volume":"394","author":"Fonovic","year":"2013","journal-title":"Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0265","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nn.2511","article-title":"Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer\u2019s disease","volume":"13","author":"Fuhrmann","year":"2010","journal-title":"Nature Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096372","article-title":"The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site","volume":"9","author":"Fujita","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107989_bb0275","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/glia.22474","article-title":"CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice","volume":"61","author":"Fumagalli","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0280","doi-asserted-by":"crossref","first-page":"702639","DOI":"10.3389\/fnagi.2021.702639","article-title":"alpha-Synuclein as a biomarker of Parkinson\u2019s disease: Good, but not good enough","volume":"13","author":"Ganguly","year":"2021","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0285","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jlb.67.4.577","article-title":"NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS","volume":"67","author":"Garcia","year":"2000","journal-title":"Journal of Leukocyte Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0290","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4049\/jimmunol.1300040","article-title":"Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation","volume":"191","author":"Garcia","year":"2013","journal-title":"Journal of immunology (Baltimore, Md: 1950)"},{"issue":"41","key":"10.1016\/j.pharmthera.2021.107989_bb0295","doi-asserted-by":"crossref","first-page":"37993","DOI":"10.1074\/jbc.M106434200","article-title":"Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1)","volume":"276","author":"Garton","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0300","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024125","article-title":"Genetics of amyotrophic lateral sclerosis","volume":"8","author":"Ghasemi","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107989_bb0305","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/jcbfm.2013.102","article-title":"Cerebral ischemic stroke: is gender important?","volume":"33","author":"Gibson","year":"2013","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0310","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41593-019-0419-y","article-title":"Sensory lesioning induces microglial synapse elimination via ADAM10 and fractalkine signaling","volume":"22","author":"Gunner","year":"2019","journal-title":"Nature Neuroscience"},{"issue":"Pt 4","key":"10.1016\/j.pharmthera.2021.107989_bb0315","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/aww017","article-title":"Early and protective microglial activation in Alzheimer\u2019s disease: A prospective study using 18F-DPA-714 PET imaging","volume":"139","author":"Hamelin","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/mds.28264","article-title":"Inflammation in experimental models of alpha-synucleinopathies","volume":"36","author":"Harms","year":"2021","journal-title":"Mov Disord"},{"issue":"18","key":"10.1016\/j.pharmthera.2021.107989_bb0325","doi-asserted-by":"crossref","first-page":"10896","DOI":"10.1073\/pnas.95.18.10896","article-title":"Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia","volume":"95","author":"Harrison","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0330","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/1673-5374.244793","article-title":"Neuronal autophagy aggravates microglial inflammatory injury by downregulating CX3CL1\/fractalkine after ischemic stroke","volume":"14","author":"He","year":"2019","journal-title":"Neural Regeneration Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0335","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0340","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3389\/fimmu.2019.02780","article-title":"Heterozygous CX3CR1 deficiency in microglia restores neuronal \u03b2-amyloid clearance pathways and slows progression of Alzheimer\u2019s like-disease in PS1-APP mice","volume":"10","author":"Hickman","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0345","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/mp.2017.246","article-title":"Markers of microglia in post-mortem brain samples from patients with Alzheimer\u2019s disease: A systematic review","volume":"23","author":"Hopperton","year":"2018","journal-title":"Molecular Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0350","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1096\/fj.05-5465com","article-title":"The neuronal chemokine CX3CL1\/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system","volume":"20","author":"Huang","year":"2006","journal-title":"The FASEB Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0355","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood-2002-12-3775","article-title":"The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion","volume":"102","author":"Hundhausen","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(01)01302-4","article-title":"The clinical picture of neuropathic pain","volume":"429","author":"Jensen","year":"2001","journal-title":"European Journal of Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0365","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1177\/147323001003800412","article-title":"Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: An Alzheimer\u2019s disease mouse model","volume":"38","author":"Jiang","year":"2010","journal-title":"The Journal of International Medical Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0370","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/mi.10.5.3","article-title":"Fractalkine\/CX3CL1: A potential new target for inflammatory diseases","volume":"10","author":"Jones","year":"2010","journal-title":"Molecular Interventions"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107989_bb0375","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1128\/MCB.20.11.4106-4114.2000","article-title":"Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion","volume":"20","author":"Jung","year":"2000","journal-title":"Molecular and Cellular Biology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2021.107989_bb0380","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0165-5728(03)00085-7","article-title":"CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system","volume":"137","author":"Kastenbauer","year":"2003","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0385","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fncel.2020.00163","article-title":"Reduced fractalkine levels lead to striatal synaptic plasticity deficits in Huntington\u2019s disease","volume":"14","author":"Kim","year":"2020","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"22","key":"10.1016\/j.pharmthera.2021.107989_bb0390","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1182\/blood-2011-04-348946","article-title":"In vivo structure\/function and expression analysis of the CX3C chemokine fractalkine","volume":"118","author":"Kim","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0395","doi-asserted-by":"crossref","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson\u2019s disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107989_bb0400","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/1567205017666201109095657","article-title":"Cerebrospinal fluid and blood CX3CL1 as a potential biomarker in early diagnosis and prognosis of dementia","volume":"17","author":"Kulczy\u0144ska-Przybik","year":"2020","journal-title":"Current Alzheimer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107989_bb0405","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.4049\/jimmunol.180.11.7590","article-title":"Activity of adenosine receptors type 1 is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons","volume":"180","author":"Lauro","year":"2008","journal-title":"Journal of Immunology"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0410","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/npp.2010.26","article-title":"Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death","volume":"35","author":"Lauro","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0415","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fncel.2014.00472","article-title":"Fractalkine\/CX3CL1 engages different neuroprotective responses upon selective glutamate receptor overactivation","volume":"8","author":"Lauro","year":"2015","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0420","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fncel.2019.00414","article-title":"Fractalkine modulates microglia metabolism in brain ischemia","volume":"13","author":"Lauro","year":"2019","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107989_bb0425","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.neurobiolaging.2012.12.014","article-title":"Aging enhances classical activation but mitigates alternative activation in the central nervous system","volume":"34","author":"Lee","year":"2013","journal-title":"Neurobiology of Aging"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0430","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2353\/ajpath.2010.100265","article-title":"CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer\u2019s disease mouse models","volume":"177","author":"Lee","year":"2010","journal-title":"The American Journal of Pathology"},{"issue":"37","key":"10.1016\/j.pharmthera.2021.107989_bb0435","doi-asserted-by":"crossref","first-page":"12538","DOI":"10.1523\/JNEUROSCI.0853-14.2014","article-title":"Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway","volume":"34","author":"Lee","year":"2014","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0440","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fncel.2014.00229","article-title":"Modulating neurotoxicity through CX3CL1\/CX3CR1 signaling","volume":"8","author":"Limatola","year":"2014","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0445","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1515\/hsz-2018-0204","article-title":"Evidence for a protective role of the CX3CL1\/CX3CR1 axis in a model of amyotrophic lateral sclerosis","volume":"400","author":"Liu","year":"2019","journal-title":"Biological Chemistry"},{"issue":"13\u201314","key":"10.1016\/j.pharmthera.2021.107989_bb0450","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.cca.2011.03.036","article-title":"Fractalkine\/CX3CR1 and atherosclerosis","volume":"412","author":"Liu","year":"2011","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0455","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lfs.2017.06.012","article-title":"Role of fractalkine\/CX3CR1 signaling pathway in the recovery of neurological function after early ischemic stroke in a rat model","volume":"184","author":"Liu","year":"2017","journal-title":"Life Sciences"},{"issue":"50","key":"10.1016\/j.pharmthera.2021.107989_bb0460","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1523\/JNEUROSCI.4403-10.2010","article-title":"CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-\u03b2 phagocytosis","volume":"30","author":"Liu","year":"2010","journal-title":"The Journal of Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0465","doi-asserted-by":"crossref","first-page":"e96528","DOI":"10.1371\/journal.pone.0096528","article-title":"CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis","volume":"9","author":"Lopez-Lopez","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0470","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1007\/s12035-017-0489-3","article-title":"Association of the CX3CR1-V249I variant with neurofibrillary pathology progression in late-onset Alzheimer\u2019s disease","volume":"55","author":"L\u00f3pez-L\u00f3pez","year":"2018","journal-title":"Molecular Neurobiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0475","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.163.3.1628","article-title":"Characterization of fractalkine in rat brain cells: Migratory and activation signals for CX3CR-1-expressing microglia","volume":"163","author":"Maciejewski-Lenoir","year":"1999","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0480","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neuropharm.2016.12.001","article-title":"Noradrenaline induces CX3CL1 production and release by neurons","volume":"114","author":"Madrigal","year":"2017","journal-title":"Neuropharmacology"},{"issue":"Pt 6","key":"10.1016\/j.pharmthera.2021.107989_bb0485","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/brain\/awv081","article-title":"Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain","volume":"138","author":"Maphis","year":"2015","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0490","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1006\/nimg.2001.0899","article-title":"Differential working memory load effects after mild traumatic brain injury","volume":"14","author":"McAllister","year":"2001","journal-title":"Neuroimage"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107989_bb0495","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1172\/JCI16790","article-title":"Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans","volume":"111","author":"McDermott","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0500","first-page":"303","article-title":"Fractalkine signaling attenuates perivascular clustering of microglia and fibrinogen leakage during systemic inflammation in mouse models of diabetic retinopathy","volume":"10","author":"Mendiola","year":"2016","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"14","key":"10.1016\/j.pharmthera.2021.107989_bb0505","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1073\/pnas.090017497","article-title":"Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival","volume":"97","author":"Meucci","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107989_bb0510","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.2004.03709.x","article-title":"Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats","volume":"20","author":"Milligan","year":"2004","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0515","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1742-2094-9-193","article-title":"Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis","volume":"9","author":"Mills","year":"2012","journal-title":"Journal of Neuroinflammation"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0520","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4049\/jimmunol.1100421","article-title":"The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood","volume":"188","author":"Mizutani","year":"2012","journal-title":"Journal of Immunology (Baltimore, Md: 1950)"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107989_bb0525","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.4049\/jimmunol.179.11.7478","article-title":"Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine","volume":"179","author":"Mizutani","year":"2007","journal-title":"Journal of Immunology"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0530","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V97.7.1925","article-title":"Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease","volume":"97","author":"Moatti","year":"2001","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.pharmthera.2021.107989_bb0535","doi-asserted-by":"crossref","first-page":"14592","DOI":"10.1523\/JNEUROSCI.0539-12.2012","article-title":"The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson\u2019s disease","volume":"32","author":"Morganti","year":"2012","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0540","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fphar.2015.00040","article-title":"Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors","volume":"6","author":"de Munnik","year":"2015","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107989_bb0545","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.neurobiolaging.2012.12.011","article-title":"Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy","volume":"34","author":"Nash","year":"2013","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0550","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/mt.2014.175","article-title":"Fractalkine over expression suppresses alpha-synuclein-mediated neurodegeneration","volume":"23","author":"Nash","year":"2015","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/gtc.12013","article-title":"Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history","volume":"18","author":"Nomiyama","year":"2013","journal-title":"Genes to Cells"},{"issue":"Pt A","key":"10.1016\/j.pharmthera.2021.107989_bb0560","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuropharm.2014.10.028","article-title":"Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease","volume":"96","author":"Norden","year":"2015","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031115","article-title":"Innate immunity: A common denominator between neurodegenerative and neuropsychiatric diseases","volume":"21","author":"Novellino","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0570","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-2094-8-9","article-title":"CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson\u2019s disease","volume":"8","author":"Pabon","year":"2011","journal-title":"Journal of Neuroinflammation"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0575","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1097\/HTR.0000000000000335","article-title":"Postconcussive symptoms over the first 14 days after mild traumatic brain injury: An experience sampling study","volume":"33","author":"Pacella","year":"2018","journal-title":"The Journal of Head Trauma Rehabilitation"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071687","article-title":"Inflammation in Parkinson\u2019s disease: Mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells"},{"issue":"22","key":"10.1016\/j.pharmthera.2021.107989_bb0585","doi-asserted-by":"crossref","first-page":"8465","DOI":"10.1073\/pnas.0602979103","article-title":"Anomalous levels of Cl- transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory","volume":"103","author":"Palma","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6048","key":"10.1016\/j.pharmthera.2021.107989_bb0590","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.1202529","article-title":"Synaptic pruning by microglia is necessary for normal brain development","volume":"333","author":"Paolicelli","year":"2011","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107989_bb0595","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1523\/JNEUROSCI.17-10-03727.1997","article-title":"Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus","volume":"17","author":"Parent","year":"1997","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0600","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fnins.2018.00609","article-title":"Decreased CX3CL1 levels in the cerebrospinal fluid of patients with Alzheimer\u2019s disease","volume":"12","author":"Perea","year":"2018","journal-title":"Frontiers in Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107989_bb0605","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/01.WCB.0000133470.91843.72","article-title":"The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury","volume":"24","author":"Rancan","year":"2004","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0610","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0074-7742(07)82010-1","article-title":"Chemokines and chemokine receptors: Multipurpose players in neuroinflammation","volume":"82","author":"Ransohoff","year":"2007","journal-title":"International Review of Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0615","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1742-2094-7-87","article-title":"CCL2\/CCR2 and CX3CL1\/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration","volume":"7","author":"Raoul","year":"2010","journal-title":"Journal of Neuroinflammation"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0620","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nn0706-859","article-title":"Fractalkine: Moving from chemotaxis to neuroprotection","volume":"9","author":"R\u00e9","year":"2006","journal-title":"Nature Neuroscience"},{"issue":"14","key":"10.1016\/j.pharmthera.2021.107989_bb0625","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1073\/pnas.1316510111","article-title":"Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis","volume":"111","author":"Ridderstad Wollberg","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0630","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1073\/pnas.92.3.689","article-title":"Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis","volume":"92","author":"Ripps","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107989_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165197","article-title":"Progesterone attenuates microglial-driven retinal degeneration and stimulates protective fractalkine-CX3CR1 signaling","volume":"11","author":"Roche","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0640","doi-asserted-by":"crossref","first-page":"43067","DOI":"10.1038\/srep43067","article-title":"Fractalkine-CX3CR1 signaling is critical for progesterone-mediated neuroprotection in the retina","volume":"7","author":"Roche","year":"2017","journal-title":"Scientific Reports"},{"issue":"45","key":"10.1016\/j.pharmthera.2021.107989_bb0645","doi-asserted-by":"crossref","first-page":"16241","DOI":"10.1523\/JNEUROSCI.3667-11.2011","article-title":"CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity","volume":"31","author":"Rogers","year":"2011","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107989_bb0650","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/epi.12354","article-title":"Fractalkine\/CX3CL1 modulates GABAA currents in human temporal lobe epilepsy","volume":"54","author":"Roseti","year":"2013","journal-title":"Epilepsia"},{"issue":"22","key":"10.1016\/j.pharmthera.2021.107989_bb0655","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0660","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1742-2094-10-108","article-title":"Fractalkine (CX3CL1) enhances hippocampal N-methyl-D-aspartate receptor (NMDAR) function via D-serine and adenosine receptor type A2 (A2AR) activity","volume":"10","author":"Scianni","year":"2013","journal-title":"Journal of Neuroinflammation"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0665","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1152\/jn.00348.2020","article-title":"Spinal cord fractalkine (CX3CL1) signaling is critical for neuronal sensitization in experimental nonspecific, myofascial low back pain","volume":"125","author":"Sessler","year":"2021","journal-title":"Journal of Neurophysiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0670","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.neurobiolaging.2009.03.004","article-title":"New evidences for fractalkine\/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson\u2019s disease","volume":"32","author":"Shan","year":"2011","journal-title":"Neurobiology of Aging"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0675","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s11064-017-2449-8","article-title":"Up-regulation of CX3CL1 via STAT3 contributes to SMIR-induced chronic postsurgical pain","volume":"43","author":"Shen","year":"2018","journal-title":"Neurochemical Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107989_bb0680","doi-asserted-by":"crossref","first-page":"130181","DOI":"10.1098\/rsob.130181","article-title":"Neuron-glia crosstalk in health and disease: Fractalkine and CX3CR1 take centre stage","volume":"3","author":"Sheridan","year":"2013","journal-title":"Open Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0685","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"Shi","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0690","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-804766-8.00013-3","article-title":"Alzheimer\u2019s disease","volume":"167","author":"Soria Lopez","year":"2019","journal-title":"Handbook of Clinical Neurology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2021.107989_bb0695","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-5728(02)00033-4","article-title":"Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury","volume":"125","author":"Soriano","year":"2002","journal-title":"Journal of Neuroimmunology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2021.107989_bb0700","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2011.12.028","article-title":"The association of V249I and T280M fractalkine receptor haplotypes with disease course of multiple sclerosis","volume":"245","author":"Stojkovi\u0107","year":"2012","journal-title":"Journal of Neuroimmunology"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0705","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00702-015-1369-5","article-title":"Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer\u2019s disease progression: CX3CL1, TREM2, and PPARgamma","volume":"122","author":"Strobel","year":"2015","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0710","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.25095","article-title":"Neuronal vulnerability, pathogenesis, and Parkinson\u2019s disease","volume":"28","author":"Sulzer","year":"2013","journal-title":"Movement Disorders"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0715","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1742-2094-2-17","article-title":"CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: Kinetics and cellular origin","volume":"2","author":"Sunnemark","year":"2005","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0720","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1742-2094-11-26","article-title":"CX3CR1 deficiency suppresses activation and neurotoxicity of microglia\/macrophage in experimental ischemic stroke","volume":"11","author":"Tang","year":"2014","journal-title":"Journal of Neuroinflammation"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107989_bb0725","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1046\/j.1460-9568.2002.02007.x","article-title":"Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat","volume":"15","author":"Tarozzo","year":"2002","journal-title":"The European Journal of Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107989_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140566","article-title":"Fractalkine signaling regulates the inflammatory response in an \u03b1-synuclein model of Parkinson disease","volume":"10","author":"Thome","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0735","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tins.2004.12.002","article-title":"Neuropathic pain and spinal microglia: A big problem from molecules in \u201csmall\u201d glia","volume":"28","author":"Tsuda","year":"2005","journal-title":"Trends in Neurosciences"},{"issue":"2 Suppl","key":"10.1016\/j.pharmthera.2021.107989_bb0740","first-page":"S15","article-title":"Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis","volume":"19","author":"Tullman","year":"2013","journal-title":"The American Journal of Managed Care"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107989_bb0745","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1096\/fj.04-1862fje","article-title":"The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration","volume":"18","author":"Tuo","year":"2004","journal-title":"The FASEB Journal"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0750","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jnnp.74.7.995","article-title":"Prolonged survival in motor neuron disease: A descriptive study of the King\u2019s database 1990-2002","volume":"74","author":"Turner","year":"2003","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0755","doi-asserted-by":"crossref","first-page":"577380","DOI":"10.1016\/j.jneuroim.2020.577380","article-title":"Inflammation in Huntington\u2019s disease: A few new twists on an old tale","volume":"348","author":"Valadao","year":"2020","journal-title":"Journal of Neuroimmunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0760","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0765","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.conb.2015.10.004","article-title":"Microglial genes regulating neuroinflammation in the progression of Alzheimer\u2019s disease","volume":"36","author":"Villegas-Llerena","year":"2016","journal-title":"Current Opinion in Neurobiology"},{"issue":"13","key":"10.1016\/j.pharmthera.2021.107989_bb0770","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1523\/JNEUROSCI.4363-08.2009","article-title":"Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals","volume":"29","author":"Wake","year":"2009","journal-title":"The Journal of Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0775","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13024-018-0296-y","article-title":"Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model","volume":"13","author":"Wang","year":"2018","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0780","doi-asserted-by":"crossref","DOI":"10.1177\/1744806917726256","article-title":"Upregulation of CX3CL1 mediated by NF-kappaB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration","volume":"13","author":"Wang","year":"2017","journal-title":"Molecular Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0785","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41598-017-18774-0","article-title":"Ischemia-induced neuronal cell death is mediated by chemokine receptor CX3CR1","volume":"8","author":"Wang","year":"2018","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb9182","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41598-017-18774-0","article-title":"Ischemia-induced Neuronal Cell Death Is Mediated by Chemokine Receptor CX3CR1","volume":"558","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107989_bb0790","doi-asserted-by":"crossref","first-page":"254","DOI":"10.14336\/AD.2019.0615","article-title":"Disease progression-dependent expression of CD200R1 and CX3CR1 in mouse models of Parkinson\u2019s disease","volume":"11","author":"Wang","year":"2020","journal-title":"Aging and Disease"},{"issue":"20","key":"10.1016\/j.pharmthera.2021.107989_bb0795","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.1073\/pnas.1901787116","article-title":"Soluble CX3CL1 gene therapy improves cone survival and function in mouse models of retinitis pigmentosa","volume":"116","author":"Wang","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0800","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2021.02.053","article-title":"CX3CR1 deficiency aggravates brain white matter injury and affects expression of the CD36\/15LO\/NR4A1 signal","volume":"549","author":"Wang","year":"2021","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0805","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/ATVBAHA.111.237412","article-title":"Fractalkine: A survivor\u2019s guide: Chemokines as antiapoptotic mediators","volume":"32","author":"White","year":"2012","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0810","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12974-020-01828-y","article-title":"Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice","volume":"17","author":"Winter","year":"2020","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0815","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fncel.2013.00026","article-title":"Microglia, seen from the CX3CR1 angle","volume":"7","author":"Wolf","year":"2013","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0820","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059586","article-title":"Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer\u2019s disease","volume":"8","author":"Wright","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107989_bb0825","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.bbi.2010.05.011","article-title":"Protracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challenge","volume":"24","author":"Wynne","year":"2010","journal-title":"Brain, Behavior, and Immunity"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0830","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0896-6273(02)00794-8","article-title":"Inflammation in neurodegenerative disease\u2014A double-edged sword","volume":"35","author":"Wyss-Coray","year":"2002","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0835","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4103\/1673-5374.156979","article-title":"CX3 chemokine receptor 1 deficiency leads to reduced dendritic complexity and delayed maturation of newborn neurons in the adult mouse hippocampus","volume":"10","author":"Xiao","year":"2015","journal-title":"Neural Regeneration Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107989_bb0840","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.ajpath.2012.01.024","article-title":"Altered expression of CX3CL1 in patients with epilepsy and in a rat model","volume":"180","author":"Xu","year":"2012","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0845","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fnagi.2017.00193","article-title":"Microglial activation in the pathogenesis of Huntington\u2019s disease","volume":"9","author":"Yang","year":"2017","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107989_bb0850","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1136\/bjo.2009.165811","article-title":"Polymorphisms in CFH, HTRA1 and CX3CR1 confer risk to exudative age-related macular degeneration in Han Chinese","volume":"94","author":"Yang","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107989_bb0855","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jneuroim.2011.03.005","article-title":"The roles of fractalkine\/CX3CR1 system in neuronal death following pilocarpine-induced status epilepticus","volume":"234","author":"Yeo","year":"2011","journal-title":"Journal of Neuroimmunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0860","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama","year":"2007","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107989_bb0865","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/glia.23016","article-title":"Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa","volume":"64","author":"Zabel","year":"2016","journal-title":"Glia"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107989_bb0870","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1089\/neu.2015.4041","article-title":"Fractalkine receptor deficiency is associated with early protection but late worsening of outcome following brain trauma in mice","volume":"33","author":"Zanier","year":"2016","journal-title":"Journal of Neurotrauma"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0875","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nn.3641","article-title":"Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior","volume":"17","author":"Zhan","year":"2014","journal-title":"Nature Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107989_bb0880","first-page":"233","article-title":"Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases","volume":"3","author":"Zhang","year":"2010","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107989_bb0885","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1111\/jnc.15324","article-title":"PSD-93 mediates the crosstalk between neuron and microglia and facilitates acute ischemic stroke injury by binding to CX3CL1","volume":"157","author":"Zhang","year":"2021","journal-title":"J Neurochem"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107989_bb0890","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1167\/iovs.15-16830","article-title":"Associations between the T280M and V249I SNPs in CX3CR1 and the risk of age-related macular degeneration","volume":"56","author":"Zhang","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0895","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.21037\/apm-20-1078","article-title":"MMP-9 regulates CX3CL1\/CX3CR1 in the early phase of neuropathic pain in chronic sciatic nerve constriction injury (CCI) rats","volume":"9","author":"Zhao","year":"2020","journal-title":"Annals of Palliative Medicine"},{"key":"10.1016\/j.pharmthera.2021.107989_bb0900","doi-asserted-by":"crossref","first-page":"480702","DOI":"10.1155\/2013\/480702","article-title":"Elevated expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the dorsal root ganglia and spinal cord in experimental autoimmune encephalomyelitis: Implications in multiple sclerosis-induced neuropathic pain","volume":"2013","author":"Zhu","year":"2013","journal-title":"BioMed Research International"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107989_bb0905","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V","article-title":"Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation","volume":"29","author":"Zujovic","year":"2000","journal-title":"Glia"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2021.107989_bb0910","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0165-5728(01)00259-4","article-title":"In vivo neutralization of endogenous brain fractalkine increases hippocampal TNFalpha and 8-isoprostane production induced by intracerebroventricular injection of LPS","volume":"115","author":"Zujovic","year":"2001","journal-title":"Journal of Neuroimmunology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:23:46Z","timestamp":1759011826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821001911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":183,"alternative-id":["S0163725821001911"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107989","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CX3CL1\/CX3CR1 signaling targets for the treatment of neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107989"}}